Key Facts and Milestones

Fast Facts

  • The Feinstein Institute currently has more than 2,000 clinical research studies being conducted with more than 15,000 participants enrolled each year.
  • Our state-of-the-art laboratories provide the infrastructure needed to conduct groundbreaking, disease-oriented research. They also house the largest genotyping facility in the state of New York.
  • The Feinstein Institute ranks in the top 6th percentile of all National Institutes of Health (NIH) grants awarded to research centers.
  • Our researchers are regularly published in major peer-reviewed journals such as The New England Journal of MedicineProceedings of the National Academy of ScienceNature and others.
  • The Feinstein Institute has produced more than 200 patents in 80 distinct technologies and has generated a dozen successful biotech start-ups.

Key Milestones

  • 1975 Kanti Rai, MD, and others at LIJ Medical Center create a clinical staging system for chronic lymphocytic leukemia – one of the most common forms of adult leukemia. The system is still used around the world today.
  • 1980 John M. Kane, MD, and colleagues at Zucker Hillside Hospital publish a landmark study of the drug Chloral, which leads to FDA approval of the first atypical, antipsychotic drug. The study is one of the most frequently cited studies in the field of psychiatry.
  • 1998 David Eidelberg, MD, and colleagues discover metabolic abnormalities in the brains of patients with Parkinson’s disease using positron emission tomography (PET) imaging, a new way to diagnose the disease.
  • 1999 North Shore-LIJ Health System establishes the North Shore-LIJ Health Research Institute as an independently chartered, not-forprofit research corporation. Nicholas Chiorazzi, MD, assumes role of founding president and chief executive officer.
  • 2000 Kevin J. Tracey, MD, and colleagues discover the cholinergic anti-inflammatory pathway, through which the brain directly controls the immune system.
  • 2005 The North Shore-LIJ Research Institute is renamed The Feinstein Institute for Medical Research in recognition of the largest single gift in the history of the health system from Bed Bath & Beyond cofounder Leonard Feinstein and his wife Susan. Kevin J. Tracey, MD, becomes president and chief executive officer.
  • 2006 Betty Diamond, MD, and colleagues discover why many patients with lupus develop cognitive impairment.
  • 2006 Todd Lencz, PhD, and colleagues discover a genetic mutation that predicts response to medication in first episode schizophrenia, an important step toward personalized medicine.
  • 2008 The Feinstein Institute signs a collaboration agreement with the Karolinska Institute in Sweden, home of the Nobel Prize.
  • 2008 The North Shore-LIJ Graduate School of Molecular Medicine changes its name to the Elmezzi Graduate School of Molecular Medicine, which received its initial charter to grant PhD degrees to recent medical school graduates in 1993.
  • 2010 Christopher J. Czura, PhD, Jared Huston, MD, and colleagues discover the “neural tourniquet,” a technology that uses electrical nerve stimulation to control bleeding.
  • 2011 Peter Davies, PhD and his colleagues discover that a molecule called c-Abl, which has a known role in leukemia, also has a hand in Alzheimer’s disease. The finding offers a new target for drug development that could stave off the pathological disease process.
  • 2013 Peter K. Gregersen, MD, is awarded the prestigious $600,000 Crafoord Prize for his lifelong research on rheumatoid arthritis.
  • 2014 As reported in the cover story of The New York Times Magazine, Feinstein Institute President Kevin J. Tracey, MD, is featured as discovering a new approach to treating disease by stimulating nerves, called bioelectronic medicine.
  • 2015 Peter Davies, PhD, receives the 2015 Potamkin Prize for Research in Pick’s, Alzheimer’s and Related Diseases at the American Academy of Neurology’s 67th Annual Meeting, the world’s largest gathering of neurologists.
  • 2015 Bettie Steinberg, PhD, receives the Lifetime Achievement Award from the International Papillomavirus Society for her discovery of a drug target for life-threatening respiratory cancer.
  • 2015 Chad Bouton, a renowned leader in devices that decode brain waves enabling paralyzed patients to move their limbs or drive a wheelchair, joins the Feinstein Institute.
  • 2015 The Feinstein Institute announces an inter-institutional collaboration with Cold Spring Harbor Laboratory focused on the molecular and clinical science of cancer.
  • 2015 Kanti Rai, MD, receives the 2014 Wallace H. Coulter Award for Lifetime Achievement in Hematology from the American Society of Hematology for his career contributions in leukemia research.
  • 2016 Kevin J. Tracey, MD, conducts a first-in-human clinical trial which demonstrates that stimulating the vagus nerve with an implantable bioelectronic device significantly improves measures of disease activity in patients with rheumatoid arthritis.
  • 2016 The Feinstein Institute convenes the Key Symposium, a first-of-its-kind gathering, where researchers from some of the world’s leading universities and institutions gathered to discuss the various applications of bioelectronic medicine.
  • 2016 Chad Bouton is the lead author of a paper detailing groundbreaking technology that allows a young paralyzed man to move his fingers, hand and wrist again.
  • 2016 The Feinstein Institute opens the first class 100 clean room in Nassau County as part of the expansion of its Center for Bioelectronic Medicine.

To view our most recent annual report, click here.